IM
IMTX.US Immatics NV
- Market cap
- USD 973M
- P/E
- -
- P/B
- 2.00x
- ROE
- -59.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is IMTX.US undervalued?
Graham numberThe Graham number of Immatics NV cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Immatics NV fundamental analysis
No fundamental analysis for Immatics NV yet.
Immatics NV stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Immatics NV
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME c…
Full company profileImmatics NV financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Immatics NV annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 3.77M | 18.4M | 31.3M | 34.8M | 173M | 54.0M | 156M | 48.3M | 31.6M |
| Gross Profit | -30.2M | -21.6M | -35.8M | 34.8M | 173M | 54.0M | 156M | 48.3M | 31.6M |
| Operating Income | -34.4M | -33.0M | -69.7M | -86.3M | 30.0M | -102M | -38.6M | -182M | -282M |
| EBITDA | -30.2M | -28.5M | -65.3M | -87.5M | 50.0M | -88.9M | 34.5M | -185M | -250M |
| Net Income | -31.4M | -31.7M | -211M | -93.3M | 27.7M | -94.6M | 15.2M | -196M | -262M |
| EPS | -0.50 | -0.50 | -4.40 | -1.48 | 0.41 | -1.18 | 0.14 | -1.61 | -1.81 |
| Balance Sheet | |||||||||
| Total Assets | 61.3M | 134M | 255M | 175M | 408M | 510M | 696M | 562M | 566M |
| Total Liabilities | 70.5M | 175M | 167M | 151M | 204M | 292M | 121M | 78.2M | 127M |
| Shareholders' Equity | -10.4M | -41.9M | 87.4M | 24.1M | 203M | 218M | 575M | 484M | 438M |
| Cash & Short-term Investments | 52.5M | 119M | 232M | 145M | 362M | 426M | 604M | 469M | 277M |
| Total Debt | - | 3.23M | 6.19M | 9.85M | 14.6M | 15.4M | 16.2M | 15.6M | 14.0M |
| Cash Flow | |||||||||
| Operating Cash Flow | 20.7M | 71.0M | -85.6M | -81.8M | 100M | 18.2M | -158M | -170M | -220M |
| Capital Expenditure | 507K | 2.23M | 7.52M | 5.66M | 6.22M | 31.0M | 16.5M | 6.30M | 3.28M |
| Free Cash Flow | 20.2M | 68.7M | -93.1M | -87.4M | 93.9M | -12.7M | -175M | -176M | -223M |
| Ratios | |||||||||
| ROE | - | - | -241.8% | -387.9% | 13.6% | -43.5% | 2.6% | -40.6% | -59.7% |
| ROA | -51.3% | -23.6% | -83.0% | -53.4% | 6.8% | -18.6% | 2.2% | -34.9% | -46.3% |
| Net Profit Margin | -834.1% | -172.0% | -676.0% | -268.5% | 16.0% | -175.3% | 9.8% | -407.0% | -829.1% |
| Debt to Equity | - | - | 0.07x | 0.41x | 0.07x | 0.07x | 0.03x | 0.03x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Immatics NV dividends
Immatics NV has not paid dividends in the last 8 fiscal years.
Who owns Immatics NV
- Insiders 15.95%
- Institutions 68.22%
- Public & others 15.84%
- Shares outstanding 152M
- Free float 78.0M
Top funds holding IMTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| T. Rowe Price Small-Cap Stock | 6.26M | 4.11% | +4.89% | Sep 2026 |
| T. Rowe Price Small-Cap Value | 5.59M | 3.67% | 0.00% | Sep 2026 |
| T. Rowe Price Instl Small-Cap Stock | 3.37M | 2.21% | +4.06% | Sep 2026 |
| abrdn World Healthcare | 775K | 0.51% | 0.00% | Sep 2026 |
| T. Rowe Price US Smlr Coms Eq A | 621K | 0.41% | -23.95% | Sep 2026 |
| abrdn Life Sciences Investors | 360K | 0.24% | -21.73% | Oct 2026 |
| Wasatch Micro Cap | 338K | 0.22% | 0.00% | Sep 2026 |
| T. Rowe Price Health Sciences | 321K | 0.21% | 0.00% | Sep 2026 |
| Northwestern Mutual Ser Small Cap Value | 315K | 0.21% | +9.79% | Sep 2026 |
| Wellington Global Hlthcr Eq USD G Ac | 312K | 0.21% | 0.00% | Sep 2026 |
| Vanguard International Explorer Inv | 272K | 0.18% | +22.80% | Sep 2026 |
| Hartford Healthcare Y | 219K | 0.14% | 0.00% | Sep 2026 |
| T. Rowe Price Spectrum Mod Gr Allc | 204K | 0.13% | +7.97% | Sep 2026 |
| State Street® SPDR® Ptf Dev Wld exUS ETF | 198K | 0.13% | 0.00% | Oct 2026 |
| TD US Small-Cap Equity - I | 197K | 0.13% | 0.00% | Jun 2026 |
| International Biotechnology Ord | 197K | 0.13% | 0.00% | Jul 2026 |
| ALPS Medical Breakthroughs ETF | 183K | 0.12% | 0.00% | Oct 2026 |
| Stt Strt®SPDR®S&PKenshoNwEcosComposETF | 181K | 0.12% | +0.08% | Oct 2026 |
| Aesculape SRI IC | 160K | 0.11% | 0.00% | Jun 2026 |
| Tema Oncology ETF | 148K | 0.10% | 0.00% | Oct 2026 |
Top institutions holding IMTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| T. Rowe Price Investment Management,Inc. | 22.4M | 14.69% | +3.29% | Jun 2026 |
| RTW INVESTMENTS, LLC | 12.9M | 8.50% | +0.60% | Jun 2026 |
| Suvretta Capital Management, LLC | 11.2M | 7.35% | 0.00% | Jun 2026 |
| Perceptive Advisors LLC | 10.4M | 6.82% | 0.00% | Jun 2026 |
| Baker Bros Advisors LP | 9.51M | 6.24% | -12.90% | Jun 2026 |
| Jefferies Financial Group Inc | 6.51M | 4.27% | +28.60% | Jun 2026 |
| Vestal Point Capital LP | 6.18M | 4.06% | 0.00% | Jun 2026 |
| Sofinnova Ventures | 3.67M | 2.41% | +1.07% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.19M | 1.44% | +1.74% | Jun 2026 |
| Citadel Advisors Llc | 1.81M | 1.19% | -2.01% | Jun 2026 |
| Wellington Management Company LLP | 1.65M | 1.08% | +5.50% | Jun 2026 |
| Point72 Asset Management, L.P. | 1.45M | 0.95% | -2.96% | Jun 2026 |
| Aberdeen Group PLC | 1.24M | 0.81% | +89.02% | Sep 2026 |
| Woodline Partners LP | 901K | 0.59% | -9.98% | Jun 2026 |
| Sphera Funds Management Ltd. | 720K | 0.47% | +3.44% | Jun 2026 |
| University Of Texas Investment Mgmt Co | 697K | 0.46% | 0.00% | Jun 2026 |
| Qube Research & Technologies | 523K | 0.34% | +42.65% | Jun 2026 |
| Boxer Capital Management, LLC | 475K | 0.31% | 0.00% | Jun 2026 |
| TD Asset Management Inc | 449K | 0.30% | -4.48% | Jun 2026 |
| Wasatch Advisors LP | 442K | 0.29% | -5.02% | Jun 2026 |
Immatics NV company profile
- Company name
- Immatics NV
- Ticker
- IMTX.US
- ISIN
- NL0015285941
- Exchange
- USA Stocks
- Listed since
- Jul 2, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 589
- Fiscal year end
- December
- Address
- Paul-Ehrlich-Strasse 15-19, Tübingen, Germany, 72076
- Phone
- 49 7071 5397 0
- Website
- immatics.com
About Immatics NV
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Immatics NV management
10- Dr. Harpreet Singh Ph.D.CEO, MD, Member of Management Board & Executive Director · born 1975
- Dr. Venkat Ramanan Ph.D.Chief Financial Officer · born 1970
- Ms. Amie KrauseChief People Officer · born 1973
- Dr. Hans-Georg Rammensee Ph.D.Co-Founder & Member of the Scientific Advisory Board
- Dr. Toni Weinschenk Ph.D.Co-Founder & Chief Innovation Officer · born 1970
- Mr. Steffen Walter Ph.D.Chief Operations Officer · born 1977
- Mr. Ephraim Hofsäß M.Sc.Vice President of SEC Reporting & Accounting
- Mr. James Pepin J.D.General Counsel & Corporate Secretary
- Ms. Lauren SchroederVice President of Marketing
- Dr. Carsten Reinhardt M.D., Ph.D.Chief Development Officer · born 1967